Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bellus Health Inc. - a GSK company
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 12 weeks.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Capable of giving signed informed consent
Refractory chronic cough (including unexplained chronic cough) for at least one year
Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose
You may not be if
Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history
Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
Respiratory tract infection within 4 weeks before screening
Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
History of malignancy in the last 5 years
History of alcohol or drug abuse within the last 3 years
Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
Previous participation in a BLU-5937 trial
Clareo Health | A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
